Pulmonary vascular disease & thromboembolismCohort study
Renal-diabetic overlap in pulmonary arterial hypertension
- retrospectively analysed an international cohort
Authors' conclusion
PAH with RD overlap is common, and has unmet therapeutic needs and worse outcomes.
Study context
- Population
- Incident patients with pulmonary arterial hypertension (PAH) diagnosed in 2001–2023, with available outcome dataeligible subjects, 234 (42%) classified as renal-diabetic (RD) · diabetes mellitus (DM) 45 · chronic kidney disease (CKD) 135 · both 54
- Participants
- 555 patients
- Exposure
- RD patients than non-RD patients
- RDn = 234
Main finding
As reported in the abstract
High mortality risk at baseline · baseline
Observational data: associations, not effects.
Further findings
Treatment with endothelin receptor antagonists · On PAH diagnosis
Single PAH therapy · On PAH diagnosis
High or intermediate-high risk · After 9 months
high
intermediate-high
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| ACM/PAH hospitalisation and ACM alone · follow-up of 2.5 (1-5) years · ACM/PAH hospitalisation | 1.45 (1.07–1.98) | P = 0.02 | |
| ACM/PAH hospitalisation and ACM alone · follow-up of 2.5 (1-5) years · ACM alone | 1.47 (1.05–2.04) | P = 0.02 | |
| 0.512Hazard ratio (log scale) |
- Treatment with endothelin receptor antagonists: p=0.04
- Single PAH therapy: p=0.06
- High or intermediate-high risk: p<0.001
High or intermediate-high risk · After 9 months
- Treatment patterns similar
Original publication
Renal-diabetic overlap in pulmonary arterial hypertension. Heart. Published 25 May 2026. doi:10.1136/heartjnl-2025-327389
Summarised from the published abstract; every number is checked against it